Vecuronium Infusion

Overview

Vecuronium is a non-depolarizing, intermediate-acting aminosteroid neuromuscular blocking agent (NMBA) that competitively antagonizes nicotinic acetylcholine receptors at the neuromuscular junction, producing skeletal muscle paralysis. It has no intrinsic analgesic or sedative properties — adequate analgesia and sedation must be ensured before and during its use.

Indications for Continuous Infusion (ICU Setting)

Based on clinical guidelines (Sustained Neuromuscular Blockade in the Adult Critically Ill Patient, p. 2):

ARDS with PaO₂/FiO₂ < 150 — early continuous NMBA infusion is suggested to improve oxygenation and reduce ventilator-induced lung injury
Life-threatening hypoxemia, respiratory acidosis, or hemodynamic compromise
Refractory shivering during therapeutic hypothermia
Facilitation of mechanical ventilation when other measures have failed

Routine use in status asthmaticus is not recommended.

Dosing

Route	Dose	Notes
IV bolus (intubation)	0.1 mg/kg	Onset ~3–5 min; duration ~25–40 min
IV bolus (maintenance)	0.01–0.015 mg/kg	Repeat as needed
Continuous IV infusion	0.8–1.2 mcg/kg/min (typical range)	Titrate to desired level of block

Use ideal body weight (IBW) or adjusted body weight (AdjBW) for obese patients — actual body weight overestimates dose and prolongs blockade (Sustained Neuromuscular Blockade, p. 2).

Monitoring

Train-of-Four (TOF) stimulation via peripheral nerve stimulator is the standard tool for monitoring depth of blockade
- Target: 1–2 twitches out of 4 for most ICU indications
- TOF alone should not be the sole monitoring modality — integrate with clinical assessment (Sustained Neuromuscular Blockade, p. 2)
Monitor for clinical signs: absence of spontaneous movement, ventilator synchrony

Pharmacokinetics

Property	Detail
Onset	3–5 minutes
Duration (bolus)	25–40 minutes
Metabolism	Hepatic (3-desacetyl-vecuronium — active metabolite)
Elimination	Biliary (primary) and renal
Protein binding	~60–80%

Hepatic/biliary disease: prolonged duration — reduce dose and monitor closely
Renal failure: active metabolite (3-desacetyl-vecuronium) accumulates — prolonged blockade possible
Hypothermia: slows metabolism and prolongs effect

Key Safety Considerations

Awareness: Vecuronium provides NO sedation or analgesia. Always co-administer adequate sedation (e.g., propofol, midazolam) and analgesia. Consider using EEG-based sedation monitoring.
Glucose management: Target blood glucose < 180 mg/dL in patients receiving continuous NMBAs (Sustained Neuromuscular Blockade, p. 2)
Physiotherapy: Patients on continuous NMBA infusion should receive a structured physiotherapy regimen to prevent critical illness myopathy and deconditioning
Pregnancy (Class C): Crosses the placenta; associated with residual clinical effects in the newborn. Avoid prolonged infusion, especially in the first trimester (Sustained Neuromuscular Blockade, p. 19)
Discontinuation at end of life: NMBAs should be stopped when life support is withdrawn

Reversal

Agent	Mechanism	Notes
Neostigmine (+ glycopyrrolate)	Acetylcholinesterase inhibitor	Effective when ≥2 TOF twitches present
Sugammadex	Encapsulates steroidal NMBAs (vecuronium/rocuronium)	Can reverse deep blockade (0 twitches); preferred for rapid reversal

Interactions

Aminoglycosides, clindamycin, magnesium: potentiate blockade
Volatile anesthetics: enhance neuromuscular blockade
Corticosteroids (especially with prolonged use): risk of critical illness myopathy
Phenytoin, carbamazepine: may reduce duration of blockade (resistance)
Succinylcholine prior to vecuronium: may potentiate subsequent non-depolarizing block

This is a shared conversation. Sign in to Orris to start your own chat.